You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽託生物(300583.SZ)2021年度預盈3563.05萬-4603.95萬元 同比扭虧為盈
格隆匯 01-27 20:59

格隆匯1月27日丨賽託生物(300583.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤3563.05萬元–4603.95萬元,上年同期為虧損17980.72萬元;扣除非經常性損益後的淨利潤2292.35萬元–3333.25萬元,上年同期為虧損18472.29萬元。業績變動原因如下:

1、報吿期內公司堅定不移地踐行產業升級戰略,打造集“醫藥中間體-高端特色原料藥-成品製劑”為一體化生物技術企業。通過研發牽引,豐富產品線、優化市場佈局。加大了高端中間體產品研發、生產和銷售力度,促進了當期主營業務收入和毛利率水平的提升。

2、公司緊抓國內經濟持續向好行業需求增長的機遇,整體產能利用率不斷提升,全產業鏈一體化佈局下的產品成本優勢逐漸突顯,同時,管理不斷精細化,產業鏈整合優勢有所體現,盈利能力較上年同期有所增強。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account